SCHEMBL12384387

SCHEMBL12384387

CC(C)(C)C1CCN(C(=O)Cc2ccccc2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.66
▸ HSD11B1 P28845 1/20 0.57
▸ ALDH1A1 P00352 6/20 0.57
▸ KDM4E B2RXH2 4/20 0.57
▸ POLB P06746 2/20 0.57
▸ TACR3 P29371 1/20 0.57
▸ HDAC3 O15379 1/20 0.55
▸ HDAC4 P56524 1/20 0.55
▸ HDAC1 Q13547 1/20 0.55
▸ HDAC7 Q8WUI4 1/20 0.55
▸ HDAC2 Q92769 1/20 0.55
▸ HDAC10 Q969S8 1/20 0.55
▸ HDAC11 Q96DB2 1/20 0.55
▸ HDAC8 Q9BY41 1/20 0.55
▸ HDAC6 Q9UBN7 1/20 0.55
▸ HDAC9 Q9UKV0 1/20 0.55
▸ HDAC5 Q9UQL6 1/20 0.55
▸ TSHR P16473 1/20 0.55
▸ USP2 O75604 1/20 0.51
▸ GAA P10253 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12424421 0.91 ALDH1A1 (0.62) L3MBTL1HSD11B1ALDH1A1KDM4EPOLB
SCHEMBL13152714 0.84 L3MBTL1 (0.64) L3MBTL1HSD11B1ALDH1A1KDM4EPOLB
SCHEMBL15014500 0.83 L3MBTL1 (0.71) L3MBTL1HSD11B1ALDH1A1KDM4EPOLB
SCHEMBL27547326 0.81 L3MBTL1 (0.79) L3MBTL1HSD11B1ALDH1A1KDM4EPOLB
SCHEMBL13181132 0.81 HDAC3 (0.68) L3MBTL1HSD11B1ALDH1A1KDM4EPOLB
SCHEMBL24663632 0.81 L3MBTL1 (0.73) L3MBTL1HSD11B1ALDH1A1KDM4EPOLB
SCHEMBL12424606 0.80 L3MBTL1 (0.68) L3MBTL1HSD11B1ALDH1A1KDM4EPOLB
SCHEMBL13629928 0.80 L3MBTL1 (0.77) L3MBTL1HSD11B1ALDH1A1KDM4EPOLB
SCHEMBL10722408 0.80 HSD11B1 (0.77) L3MBTL1HSD11B1ALDH1A1KDM4ETSHR
SCHEMBL3967794 0.80 HSD11B1 (0.77) L3MBTL1HSD11B1ALDH1A1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461328-B2 Tricyclic heterocyclic compounds, compositions and methods of use thereof GENENTECH, INC. (US) 2013-06-11 — — US disclosed
US-20110201593-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2011-08-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201593-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF CCNY, CCNA1, CCNA2 L3MBTL1 3165/4885HSD11B1 291/4885ALDH1A1 1168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback